Celiac disease
Therapeutic area
Gastroenterology
Rare disease
Yes
- Definition
- An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Celiac disease
- Therapeutic area
- Gastroenterology
- celiac disease
- celiac disease
- celiac sprue
- coeliac sprue
- gluten intolerance
- gluten-induced enteropathy
- non tropical sprue
- Severity
- Mild
- Genetic
- Hereditary
- Gastroenterology
- Immunology
- MONDO ID
- MONDO:0005130
- Parent condition
- MONDO:0000588
Related records
Broader conditions (13)
- Autoimmune disease
- Autoimmune disorder of gastrointestinal tract
- Digestive system disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
- Immune system disorder
- Intestinal disorder
- Malabsorption syndrome
- Small intestine disorder
Narrower conditions (1)
- Lane Hamilton syndrome
Trials (324)
- "Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease"
- "Gluten Friendly" Treatment in Celiac Disease
- A 12-week Exercise Program for Adults With Celiac Disease
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Blood Based Diagnostic Test for Coeliac Disease
- A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
- A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
- A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
- A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
- A Low FODMAPs Diet in Celiac Patients With Persistent Gastrointestinal Symptoms
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
- A Phase II Study of CCX282-B in Patients With Celiac Disease
- A Pilot Study to Explore the Role of Gut Flora in Celiac Disease
- A Population-based Study of Celiac Disease in South Europe in Children Between 1 to 5 Years of Age
- A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
- A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
- A Study of Guselkumab in Adult Participants With Celiac Disease
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
Approved drugs (1)
- Phytonadione
Drugs in development (17)
- Bifidobacterium SPP. Phase 1
- Guselkumab Phase 1
- Humik-beta-1 Phase 1
- Itraconazole Phase 1
- Larazotide Phase 3
- Larazotide acetate Phase 2
- Latiglutenase Phase 2
- Ordesekimab Phase 2
- Petesicatib Phase 1
- Prednisolone Phase 2
- Ritlecitinib Phase 2
- Teriflunomide Phase 1
- Vedolizumab Phase 2
- Vercirnon Phase 2
- Water Phase 1
- Zamaglutenase Phase 2
- ZED-1227 Phase 2
Other linked drugs (1)
- Rifaximin